CAMBRIDGE, Mass. and LONDON, June 22, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies,
CAMBRIDGE, Mass. and LONDON, June 22, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO) a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologic therapies,